Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
Jiajia Gu, Luxi Qian, Guojing Zhang, Nupam P. Mahajan, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun
Topics & Concepts
OsimertinibApoptosisCancer researchIn vivoCell growthCell cultureMedicineGene knockdownBiologyEpidermal growth factor receptorReceptorInternal medicineErlotinibBiochemistryGeneticsBiotechnologyLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysChronic Myeloid Leukemia Treatments